biopharmaceutical development

AnaptysBio Announces Strategic Business Split to Create Two Public Companies, Sharpening Asset Focus

4 weeks ago talkbio0Tagged AnaptysBio, asset, biopharmaceutical development, business split, Immunology, Imsidolimab, Jemperli, public companies, restructuring, royalty management

AnaptysBio; business split; royalty management; biopharmaceutical development; Jemperli; imsidolimab; public companies; immunology treatments; asset value; restructuring

BenevolentAI Embarks on Strategic Overhaul to Realign with Founding TechBio Mission

11 months ago talkbio0Tagged Artificial Intelligence, BenevolentAI, biopharmaceutical development, Drug Discovery, Kenneth, Mulvany, Strategic Overhaul, TechBio mission

BenevolentAI, strategic overhaul, TechBio mission, artificial intelligence, biopharmaceutical development, drug discovery, Kenneth Mulvany

Viridian Therapeutics’ Veligrotug Achieves Positive Topline Results in Phase 3 THRIVE Clinical Trial for Thyroid Eye Disease

1 year ago talkbio0Tagged Antibodies, biopharmaceutical development, Clinical Trials, Phase 3, Success, Thrive, Thyroid associated opthalmopathies, Veligrotug, VRDN-001

Veligrotug (VRDN-001), Thyroid Eye Disease (TED), Phase 3 THRIVE Clinical Trial, Anti-IGF-1R Antibody, Clinical Trial Success, Biopharmaceutical Development

Navigating the Complexities of Adding Rare Disease Products to Your Company’s Portfolio

1 year ago talkbio0Tagged Access, biopharmaceutical development, commercialization, Contract Strategy, Identification (Psychology), Market, Rare disease products, regulatory incentives, Technology, value-based

Rare disease products, biopharmaceutical development, commercialization, market access, patient identification, payer contract strategy, value-based contracting, regulatory incentives, emerging technology.